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Although considered highly controver-
sial just a decade ago, there is now
growing consensus among immunolo-
gists that many cancers elicit a cellular
immune response that in some cases
can influence tumor formation, growth,
and/or metastasis (Smyth et al., 2001).
Immune responses can be categorized
into two general types. Cellular, or Th1,
responses result in the stimulation of
effector cells such as cytotoxic T lym-
phocytes, whose principal
function is to kill virus-infected
cells. Alternatively, a humoral
or Th2 response is normally
elicited in response to extra-
cellular pathogens such as
bacteria and to their toxins,
and results in the formation of
specific, circulating antibod-
ies, secreted by B lympho-
cytes. A number of recent
studies using gene-targeted
mice have provided the first
strong evidence that perforin
and interferon-γ, secreted by
cytotoxic T lymphocytes and
recognized as key players in
defense against viruses, can
also be protective against car-
cinogenesis. Evidence for
immunoprotective mecha-
nisms dependent on these
molecules extends to carcino-
gen-induced sarcoma forma-
tion (van den Broek et al.,
1996; Kaplan et al., 1998),
and the development of spon-
taneous lymphoma (Smyth et
al., 2000) and certain epithe-
lial malignancies (Shankaran
et al., 2001; Smyth and
Trapani, 2001) in a number of mouse
strains. These tantalizing observations
affirm the controversial hypothesis of
cancer immune surveillance initially
enunciated by pioneers such as Burnet
and Thomas, and offer hope to
researchers and clinicians that strate-
gies to harness the immune system to
combat established cancer may hold
great promise. However, there is equally
good evidence in cancer patients that
the inherent genomic instability of can-
cers endows them with many opportuni-
ties to escape from immune control.
Most frequently, cancer cells can
become “invisible” to T lymphocytes by
losing the expression of specific class I
antigens (Lehmann et al., 1995), or fail-
ing to process the peptides these mole-
cules present to T cells. Just as discour-
aging, cancer cells can skew or stunt an
emerging cellular response by elaborat-
ing suppressive cytokines such as 
TGF-β or IL-10.
For diverse reasons, many cancer
cells are also poorly immunogenic. To be
optimally activated, T cells require two
distinct signals from antigen-presenting
cells. First, clonotypic antigen receptors
on the T cell bind to antigenic peptides
presented on MHC molecules, providing
specificity for the interaction. In addition,
“costimulation” through the binding of
receptor-ligand pairs on the T cell and
antigen-presenting cell provides a sec-
ond signal necessary for T cell prolifera-
tion and the development of efficient
effector function. Most nonhematological
malignancies do not express costimula-
tory molecules such as B7.1 (CD80) or
B7.2 (CD86) to interact with CD28 on T
cells and are therefore unable to prime
an effective immune response directly. In
this regard, an even greater problem
may be posed by the recently
published findings of Dong et
al. These investigators showed
that aberrant expression on
cancer cells of B7-H1, a newly
characterized member of the
B7 costimulatory family, result-
ed in strong promotion of tumor
growth in vivo, and could even
override an otherwise effective
immune response in a syn-
geneic cancer rejection model.
While little is known about the
normal physiological function
of B7-H1, mice that fail to
express its only known ligand,
PD-1, are prone to autoim-
mune diseases. The same
authors and other investigators
have shown that the PD-1/B7-
H1 interaction can inhibit prolif-
eration and cytokine secretion
by activated T cells. Collect-
ively, these and other findings
have been taken to indicate
that B7-H1 is involved in regu-
lating the activity of certain
autoreactive T cells (cells that
interact with self-antigens and
can cause tissue damage) and
may lead to the promotion of
Th2 responses.
Dong and collaborators now present
considerable evidence for a new form of
immune evasion resulting from T cell
apoptosis induced by their direct contact
with B7-H1-overexpressing cancer cells.
P815 mastocytoma cells transplanted
into syngeneic DBA/2 recipients form
rapidly growing tumors, unless they are
engineered to express costimulatory
B7.1 on their surface (Figure 1). This
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Recent studies have provided evidence that some cancers can aberrantly express molecules capable of inducing apopto-
sis of tumor-reactive lymphocytes. Several other potential tumor escape mechanisms that can block the cytotoxic path-
ways activated by killer T cells have also been proposed.
Figure 1. B7-H1 expression on P815 mastocytoma cells prevents rejec-
tion by syngeneic DBA/2 mice
(i) P815 cells (H-2d) grow rapidly and kill their hosts when implanted
subcutaneously. (ii) If the costimulatory molecule B7.1 is expressed on
the tumor cell surface and can bind CD28 on T cells, an effective
immune response is primed against tumor peptides presented on
MHC class I molecules, resulting in tumor rejection. (iii) B7-H1 overex-
pression in addition to B7.1 overrides the mouses ability to generate
anti-P815 immunity, restoring the virulence of the tumor and death of
the mouse. In this graphic, B7-H1 is shown hypothetically bound by its
only well-defined receptor PD-1, but alternative receptors almost cer-
tainly exist.
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leads to the priming of an effective
tumor-specific T cell response resulting
in tumor rejection after initial growth of
the cancer for several days. When P815
cells coexpressed B7-H1 in addition to
B7.1, tumor rejection did not occur;
rather, tumor growth continued unabat-
ed, and killed the recipients in a similar
timeframe as wild-type or mock-trans-
fected P815 cells. The effect was proba-
bly not due to enhanced tumor growth
per se, as B7-H1-expressing P815
tumors grew at the same rate as mock-
transfected cells in RAG-1−/− immunode-
ficient recipients. These gene-targeted
mice do not express the re-
combinase necessary for re-
arrangement of T and B cell
receptor gene segments. As
the expression of a functional
antigen receptor is necessary
for positive selection, RAG-1−/−
mice have virtually a complete
lack of all T and B cells.
Moreover, by implanting the
P815 tumor variants in the
peritoneal cavity of RAG-1−/−
mice, the authors demonstrat-
ed that B7-H1 overexpression
on the tumor cell surface could
reduce the number of tumor-
reactive T cells found in the
peritoneal cavity, by inducing
their apoptotic death. For
these experiments, T cells
from transgenic mice exp-
ressing a T cell receptor that 
recognized a P815 tumor 
peptide presented on H-2Ld
were adoptively transferred 
into tumor-bearing recipients.
Importantly, T cell apoptosis
was inhibited, and growth of
P815 cells was once more
retarded when the animals
were additionally preinfused
with a monoclonal antibody
that blocked the interaction of tumor B7-
H1 with PD-1 on the T cells. The mecha-
nism of T cell death has not been fully
elucidated, but the authors postulate this
may involve both FasL expression and
secretion of IL-10, a cytokine previously
shown to induce death of activated T
cells. A number of in vitro experiments
were also presented in which tumor cells
that were either transfected to express
B7-H1 or expressed the molecule consti-
tutively induced apoptosis in cognate T
cells with which they were mixed. T cell
death was inhibitable by adding B7-H1-
Ig fusion protein to the culture medium,
but was not dependent on PD-1 expres-
sion on the T cells. Similarly, primary T
cells incubated with B7-H1-Ig and anti-
CD3 antibody initially proliferated, then
underwent programmed cell death.
However, neither proliferation nor apop-
tosis was inhibited by PD-1-Ig. It is there-
fore very likely that T cell apoptosis 
in these experiments was mediated
through interaction of B7-H1 with an
alternative cellular receptor(s), the iden-
tity of which remains unknown.
What is the relevance of these find-
ings for human cancer? Firstly, Dong and
coworkers found a remarkably high inci-
dence of B7-H1 expression in freshly iso-
lated human cancers, including 95% of
histologically diverse lung cancers, 87%
of ovarian cancers, 100% of melanomas,
and about half of the colon cancers
examined. By comparison, juxtaposed
normal tissues in the same histological
sections expressed no B7-H1, and
expression in normal tissues was
restricted to macrophages or resident
tissue histiocytes such as liver Kuppfer
cells. The authors postulated that the
“cytokine milieu” in some cancers might
be conducive to B7-H1 expression, due
to local inflammation and the production
of interferon-γ, as this cytokine was
shown to induce B7-H1 expression on
cancer cell lines in vitro. If substantiated,
this latter observation would be at odds
with the many beneficial effects of inter-
feron-γ, which include upregulated anti-
gen presentation by the tumor, enhanced
MHC class II expression on professional
antigen-presenting cells, chemotaxis of
NK cells, and inhibition of angiogenesis.
The incidence of B7-H1 expression
reported on human tumors was also
remarkably high, and far fewer of these
tumor types typically display significant
inflammatory infiltrates. As discussed
above, caution particularly
needs to be exercised in view
of how little we know about B7-
H1 ligands other than PD-1,
and their potential functions.
Might such receptors even be
coexpressed on some cancer
cells together with B7-H1? The
intriguing set of data presented
by Dong et al. cannot exclude
the possibility that B7-H1 plays
a role in cancer biology that
might have little to do with
modulation of immune func-
tion. Clearly, the present find-
ings will have to be revisited
and further experiments per-
formed, as new information on
the function of B7-H1 and its
ligands emerges.
If corroborated, the find-
ings presented by Dong and
colleagues also have important
implications for cancer immu-
notherapy. Some immunother-
apeutic approaches to cancer
involve expanding a patient’s
tumor-reactive lymphocytes ex
vivo, by exposing them to
autologous tumor cells and
stimulatory cytokines. Clearly,
adoptive therapy using preacti-
vated T cells might fail because of T cell
deletion upon cancer cell engagement.
Alternatively, strategies aiming to raise
active T cell responses to tumor antigens
might have to consider including a strate-
gy to block B7-H1. However, as alluded
to above, such an approach might theo-
retically predispose to an unacceptable
risk of raising self-reactive T cells. It is
premature to jump to such conclusions
without further extensive in vivo studies
once the basic biology of B7-H1 and its
ligands is better understood. Preferably,
physiologically relevant models examin-
ing spontaneous and/or carcinogen-
Figure 2. Putative mechanisms for inhibition of T cell-mediated apop-
tosis following ligation of cancer cells
Several mechanisms have recently been proposed through which
tumor cells might block T cell cytolysis. FasL expression on cancer cells
has been postulated to induce death of effector T cells following
engagement of Fas, but this mechanism has not stood up to more rig-
orous testing (see text for details). In addition, it has been proposed
that some cancer cells can withstand CTL or NK cell attack by
expressing protease inhibitors (for example the serpin, PI-9) that inacti-
vate granzyme B (shown in pink, binding to its putative receptor, MPR)
by downregulating expression of granzyme receptors or by blocking
signal transduction pathways resulting in trafficking (polarization) of
T cytotoxic granules toward the immunological synapse. Perforin mol-
ecules are shown schematically in yellow.
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induced tumor formation in gene target-
ed or transgenic mice might provide
insights relevant to human carcinogene-
sis. An instructive and relevant parallel to
the current findings was the initial excite-
ment generated by several papers that
described FasL expression on tumors.
FasL, a member of the TNF family of pro-
apoptotic molecules, can induce the
death of cells that express the cognate
death ligand Fas.Theoretically, this could
lead to T cell deletion and “immune privi-
lege” status for the tumor. The resulting
predictions that FasL overexpression on
tissue allografts would delay or prevent
rejection were not fulfilled. In fact,
implantation of FasL-overexpressing
cells in mice resulted in precisely the
opposite result: even more rapid rejec-
tion and abscess formation in the trans-
planted tissue (reviewed in Restifo,
2000).
Along with the present report of
Dong and collaborators, the literature
currently contains several others postu-
lating or purporting to show inhibition of
T cell effector function as a result of
interaction with cancer cells (Figure 2).
These reports include models where
cancer cells may (i) overexpress serpins
(protease inhibitors) that block granzyme
B-mediated apoptosis (Medema et al.,
2001); (ii) downregulate expression of
purported granzyme receptors such as
the 280 kDa mannose-6-phosphate
receptor (Motyka et al., 2001), also
blocking apoptosis; or (iii) transmit a sig-
nal to cytotoxic T lymphocytes that
blocks the PI-3 kinase pathway, leading
to failure of perforin and granzyme
secretion due to dysregulated granule
trafficking (Radoja et al., 2001). Each of
these hypotheses requires further test-
ing in appropriate animal models, and
extreme caution is essential before
applying the apparently logical conse-
quences of these “lessons” to human
cancer therapy.
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salvador—The persistence of proliferation
Despite years of extensive studies on genes that regulate proliferation and cell death, two processes that must be tightly
coordinated throughout development to regulate cell number, remarkably few genes have been shown to affect both
processes. Using an elegant genetic screen in the fly eye,Tapon et al. (2002) have identified a gene, salvador, which is espe-
cially significant, because it not only regulates and coordinates both exit from the cell cycle and apoptosis, but also has a
human homolog that may play a key role in tumorigenesis.
The fly eye develops from merely 30 prog-
enitor cells into an exquisitely precise and
highly ordered structure consisting of
approximately 800 individual units or
ommatidia and numbering more than
15,000 cells. To reach this final form,
which is so beautifully regular that it has
been called a “neurocrystalline lattice”
(Ready et al., 1976), the signals for prolif-
eration, patterning, exit from the cell
cycle, differentiation, and cell death all
must be carefully regulated and coordi-
nated. The fly eye has provided a sensi-
tive system for the discovery of genes and
regulatory networks that control these
processes, but noticeably, few genes have
been shown to regulate both exit from the
cell cycle and execution of the apoptotic
program—two developmental events that
must be tightly coordinated to regulate
cell number. When these processes are
uncoupled or disrupted, the host is at risk
for developing a tumor.
Tumor suppressors are genes that,
when inactivated, confer a proliferative
advantage over normal cells. This can
occur by a variety of different mecha-
nisms and can lead to the development of
tumors, disorganized masses of tissue
that can cause the death of the host—
whether that host is a fruit fly (Woodhouse
et al., 1998) or a human being. In fact,
many, if not all, human cancers involve 
the inactivation of tumor suppressors
(Hanahan and Weinberg, 2000). These
genes comprise an important and diverse
group, and their discovery and characteri-
zation have helped us develop a deeper
understanding of cancer cell biology. To
date, a large number of tumor suppressor
genes have been reported in flies, and
many of them have human homologs that
